Global Immuno-Oncology Market Report 2018: Updated Forecasts to 2022 By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)]

DUBLIN–(BUSINESS WIRE)–The “Immuno-Oncology
Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune
Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung,
Melanoma, Leukemia, Lymphoma) – Global Forecast to 2022”
has been added to’s offering.

The global immuno-oncology market is anticipated to cross US$ 100
Billion by 2022. The report provides a detailed analysis of the global
immuno-oncology market. The report also provides the current and
forecasted market for immuno-oncology.

Furthermore, the report provides insights about the major drivers and
challenges, along with the latest trends and developments impacting the
industry growth. In addition, the report also highlights various
opportunities available for growth of the global immuno-oncology market.
Moreover, the report provides the sales of major marketed
immuno-oncology drugs.

The global immuno-oncology market has been segmented on the basis of
type of product into monoclonal antibodies, therapeutic vaccines, and
immune checkpoint inhibitors amongst others. According to the report,
monoclonal antibodies segment was estimated to account for the largest
share in 2016 due to rising prevalence of cancer rising usage in a
number of therapies (antibody-directed enzyme pro-drug therapy and radio

The report also sheds light on the geographic segmentation of the global
immuno-oncology market. In 2016, North America was estimated to account
for the largest share. Presence of major players, increased awareness
and better distribution mechanisms are some of the prominent factors
that have led to North America being the market leader.

On the basis of type of cancer, the immuno-oncology market is dominated
by Lung Cancer Melanoma applications with several companies and
academic institutions focusing on novel treatment approaches, thus
making the major contribution to the global immuno-oncology market. The
report provides the market analysis of major indications along with the
forecast till 2022.

A major focus has been on the ongoing clinical trials for the
development of innovative products. In this context, the report provides
information about the immuno-oncology programs at various stages of
clinical development. In addition, the report highlights the strategic
collaborations amongst the players for enhancing their market share.

The later part of the report discusses some of the prominent players in
the global immuno-oncology market. Market share analysis of major
players is also provided in the report. Furthermore, a brief business
overview of each player has been provided along with their product and
pipeline portfolios and recent developments. Overall, immuno-oncology is
an important and rapidly emerging field. This report will prove as a
complete source of knowledge and analysis for clients and potential

Trends Developments

  • Lucrative Investment Trend
  • Emergence of Targeted and Combination Therapies
  • NSCLC Melanoma Showing Greatest Contributions to the IO Market
  • Bristol-Myers Squibb and Merck Co: Top Immuno-Oncology Dealmakers

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Immuno-Oncology: Overview

4. Market Dynamic

5. Global Immuno-Oncology Market Outlook 2022

6. Global Immuno-Oncology Market, by Product Class

7. Global Immuno-Oncology Market, By Major Indications

8. Global Immuno-Oncology Market, By Geography

9. Trends Developments

10. Strategic Collaborations Alliances in the Immuno-Oncology Industry

11. Pipeline Analysis of Immuno-Oncology

12. Competitive Landscape

13. Key Players Analysis

  • Amgen Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson Johnson
  • Merck Co., Inc.
  • Novartis
  • Pfizer Inc

For more information about this report visit